PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [09/02/2025 14:17 PDT] PainReform Ltd. (NASDAQ:PRFX), Down By 100% ($1.74) From $1.74 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [08/29/2025 07:09 PDT] PRFX Expected to Trade Down After Bearish Patterns Develop
• [08/26/2025 07:22 PDT] PRFX Expected to Trade Down After Bearish Patterns Develop
• [08/20/2025 21:21 PDT] Market Maker Surveillance Report. PRFX, Losing Stocks With Lowest Price Friction For Wednesday, August 20th 2025
• [08/19/2025 10:30 PDT] PainReform Ltd. (NASDAQ:PRFX), Up By 100% ($1.35) From $1.346 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [08/06/2025 07:28 PDT] PRFX Expected to Trade Up After Bullish Patterns Develop